TCL Archive Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase December 31, 2010
TCL Archive FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer. July 27, 2007